This article presents practical recommendations of a panel of Italian psychiatrists based on their clinical experience in using the new antipsychotic drug ziprasidone. The article provides updates on efficacy and tolerability data and gives recommendations for dosing and switching strategies from previous treatments. Switching antipsychotic is a routine part of daily clinical practice for treating illness such as schizophrenia. A peculiar advantage of ziprasidone is its ability to begin with a therapeutic dose (80 mg/die) and to titrate up rapidly especially in acute conditions or when it is mandatory to discontinue promptly previous medication. Morever, ziprasidone has minimal side effects, such as sedation and anticholinergic effects that would result in cognitive impairment. Ziprasidone is not associated with weight gain and unlike other atypical antipsychotic drugs it does not increase metabolic risk factors for diabetes or heart disease (insulin resistance, high lipid levels). This unique side effect profile offers an useful pharmacologic alternative for patients who experienced discomforting side effects from other antipsychotics. Physicians should consider the advantages of long term efficacy, tolerability and safety of ziprasidone before selecting an antipsychotic medication for long term therapy.
|Translated title of the contribution||Switching to ziprasidone: The Italian clinical experience|
|Number of pages||15|
|Journal||Rivista di Psichiatria|
|Publication status||Published - May 2006|
ASJC Scopus subject areas
- Psychiatry and Mental health